Associations of thrombophilia, hypofibrinolysis, and retinal vein occlusion

Clinical and Applied Thrombosis/Hemostasis

Volumn 11, Issue 4, 2005, Pages 375-389

  Glueck, Charles J ^a,b   Wang, Ping ^a   Bell, Howard ^a   Rangaraj, Venkat ^a   Goldenberg, Naila ^a  

^a JEWISH HOSPITAL   (United States)

^b Cholesterol Center   (United States)

Author keywords

4g mutation of the plasminogen activator inhibitor 1 gene; Factor VIII; G1691A factor V Leiden mutation; Hypofibrinolysis; Plasminogen activator inhibitor activity (PAI Fx); Resistance to activated protein C (RAPC); Retinal vein occlusion; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; CARDIOLIPIN ANTIBODY; GENE PRODUCT; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME POLYMORPHISM; FEMALE; FIBRINOLYSIS; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HERITABILITY; HORMONE SUBSTITUTION; HUMAN; HYPOFIBRINOLYSIS; MALE; PA1 GENE; PARTIAL THROMBOPLASTIN TIME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RETINA VEIN OCCLUSION; SEROCONVERSION; SUBSTITUTION THERAPY; THROMBOPHILIA;

ADULT; AGED; CARDIOVASCULAR DISEASES; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; PROTEIN C; RETINAL VEIN OCCLUSION; RISK FACTORS; THROMBOPHILIA;

EID: 27544504297     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960501100404     Document Type: Article

References (39)

1. Glueck CJ, Bell H, Vadlamani L, et al. Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. Arch Ophthalmol 1999;117:43.
2. Greiner K, Hafner G, Dick B, et al. Retinal vascular occlusion and deficiencies in the protein C pathway. Am J Ophthalmol 1999;128:69.
3. Larsson J, Hillarp A, Olafsdottir E, et al. Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion. Acta Ophthalmol Scand 1999;77:634.
4. Hansen L, Kristensen HL, Bek T, et al. Markers of thrombophilia in retinal vein thrombosis. Acta Ophthalmol Scand 2000;78:523.
5. Scott JA, Arnold JJ, Currie JM, et al. No excess of factor V:Q506 genotype but high prevalence of anticardiolipin antibodies without antiendothelial cell antibodies in retinal vein occlusion in young cases. Ophthalmologica 2001;215:217.
6. Pianka P, Almog Y, Man O, et al. Hyperhomocystinemia in cases with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. Ophthalmology 2000;107:1588.
7. Kadayifcilar S, Ozatli D, Ozcebe O, et al. Is activated factor VII associated with retinal vein occlusion? Br J Ophthalmol 2001;85:1174.
8. Incorvaia C, Bandello F, Parmeggiani F, et al. Recurrent central retinal vein occlusion in a young thrombophilic patient with factor V Leiden mutation. Eur J Ophthalmol 2002;12:131.
9. Wenzler EM, Rademakers AJ, Boers GH, et al. Hyperhomocysteinemia in retinal artery and retinal vein occlusion. Am J Ophthalmol 1993;115:162.
10. Klein R, Klein BE, Moss SE, et al. The epidemiology of retinal vein occlusion: The Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000;98:133.
11. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999;130:643.
12. Glueck CJ, Fontaine RN, Wang P. Interaction of heritable and estrogen-induced thrombophilia: Possible etiologies for ischemic optic neuropathy and ischemic stroke. Thromb Haemost 2001;85:256.
13. Glueck CJ, Wang P, Fontaine RN, et al. Estrogen replacement therapy, thrombophilia, and atherothrombosis. Metabolism 2002;51:724.
14. Glueck CJ, Freiberg RA, Fontaine RN, et al. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop 2001;386:19.
15. Glueck CJ, Kupferminc MJ, Fontaine RN, et al. Genetic hypofibrinolysis in complicated pregnancies. Obstet Gynecol 2001;97:44.
16. Balasa W, Gruppo RA, Glueck CJ, et al. The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and plasminogen activator inhibitor-1 levels in children and adults. Thromb Haemost 1999;81:739.
17. Glueck CJ, Glueck HI, Tracy T, et al. Relationships between lipoprotein (a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer. Metabolism 1993;43:236.
18. Kupfermine MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999;340:9.
19. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111.
20. Jin Y, Dietz HC, Nurden A, et al. Single-strand conformation polymorphism analysis is a rapid and effective method for the identification of mutations and polymorphisms in the gene for glycoprotein IIIa. Blood 1993;82:2281.
21. Brandt G, Gruppo R, Glueck CJ, et al. Sensitivity, specificity and predictive value of modified assays for activated protein C resistance in children. Thromb Haemost 1998;79:567.
22. National Institutes of Health. Third Report of the National Cholesterol Education Program Export Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda, MD: National Institutes of Health; 2001. NIH Publication no. 01-3670.
23. The Lipid Research Clinics Population Studies Data Book. Volume 1. The prevalence study. US DHHS, Public Health Service, NIH publication no. 80:1527, 1980.
24. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third national health and nutrition examination survey. JAMA 2002;287:356.
25. SAS/STAT software: Changes and enhancements through release 6.12. Cary, NC: SAS Institute, 1997.
26. Marucci R, Bertini L, Liotta AA, et al. Activated protein C resistance is a risk factor for central retinal vein occlusion. Ann Med Int 2000;15:195.
27. Lerche RC, Wilhelm C, Eiffrig B, et al. Thrombophilia factors as inducers of retinal vascular occlusion. Ophthalmologe 2001;98:529.
28. Kuhli C, Hattenbach LO, Scharrer I, et al. High prevalence of resistance to APC in young cases with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002;240:163.
29. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999;93:1271.
30. Boyd S, Owens D, Gin T, et al. Plasma homocysteine, methylene tetrahydrofolate reductase C6777T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol 2001;85:1313.
31. Ventura SJ, Mosher WD, Curtin SC, et al. Trends in pregnancies and pregnancy rates by outcome: estimates for the United States, 1976-1996. Vital Health Stat 2000;21:1.
32. Hoibraaten E, Qvigstad E, Andersen TO, et al. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism-results from a randomized, double-blind, clinical trial. Thromb Haemost 2001;85:775.
33. Glueck CJ, Iyengar S, Goldenberg N, et al. Idiopathic intracranial hypertension: Associations with coagulation disorders and polycystic ovary syndrome. J Lab Clin Med 2003;142:35.
34. Post MS, Rosing J, Van Der Mooren MJ, et al. Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women. Br J Haematol 2002;119:1017.
35. Post MS, Christella M, Thomassen LG, et al. Effects of oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: A randomized, placebo-controlled study. Am J Obstet Gynecol 2003;189:1221.
36. Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994;117:429.
37. Backhouse O, Parapia L, Mahomed I, et al. Familial thrombophilia and retinal vein occlusion. Eye 2000;14:13.
38. Bick RL, Alfar H, Goedecke C. Thrombophilic causes of retinal vascular thrombosis:Etiology and treatment outcomes. Clin Appl Thromb Hemost 2002;8:315.
39. Glueck CJ, Goldenberg N, Bell H, et al. Amaurosis fugax: Associations with heritable thrombophilia. Clin Appl Thromb Hemost 2005, in press.